326 related articles for article (PubMed ID: 33610484)
1. Neutropenia Prevention in the Treatment of Post-docetaxel Metastatic, Castration-resistant Prostate Cancer With Cabazitaxel and Prednisone: A Multicenter, Open-label, Single-arm Phase IV Study.
Maluf FC; de Oliveira FAM; Liedke PER; Brust L; Inocêncio CG; Monteiro FSM; Smaletz O; Cubero DI
Clin Genitourin Cancer; 2021 Jun; 19(3):e171-e177. PubMed ID: 33610484
[TBL] [Abstract][Full Text] [Related]
2. Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
Meisel A; von Felten S; Vogt DR; Liewen H; de Wit R; de Bono J; Sartor O; Stenner-Liewen F
Eur J Cancer; 2016 Mar; 56():93-100. PubMed ID: 26829012
[TBL] [Abstract][Full Text] [Related]
3. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
4. Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme.
Heidenreich A; Bracarda S; Mason M; Ozen H; Sengelov L; Van Oort I; Papandreou C; Fossa S; Hitier S; Climent MA;
Eur J Cancer; 2014 Apr; 50(6):1090-9. PubMed ID: 24485664
[TBL] [Abstract][Full Text] [Related]
5. Impact of pegfilgrastim as primary prophylaxis for metastatic castration-resistant prostate cancer patients undergoing cabazitaxel treatment: an open-label study in Japan.
Kosaka T; Uemura H; Sumitomo M; Harada K; Sugimoto M; Hayashi N; Yoshimura K; Fukasawa S; Ecstein-Fraisse E; Sunaga Y; Oya M
Jpn J Clin Oncol; 2019 Aug; 49(8):766-771. PubMed ID: 31329922
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
Massard C; Mateo J; Loriot Y; Pezaro C; Albiges L; Mehra N; Varga A; Bianchini D; Ryan CJ; Petrylak DP; Attard G; Shen L; Fizazi K; de Bono J
Ann Oncol; 2017 Jan; 28(1):90-95. PubMed ID: 28039155
[TBL] [Abstract][Full Text] [Related]
7. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of cabazitaxel in 660 patients with metastatic castration-resistant prostate cancer in real-world settings: results of a Japanese post-marketing surveillance study.
Suzuki K; Matsubara N; Kazama H; Seto T; Tsukube S; Matsuyama H
Jpn J Clin Oncol; 2019 Dec; 49(12):1157-1163. PubMed ID: 31361807
[TBL] [Abstract][Full Text] [Related]
9. A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study.
Aggarwal R; Bryce A; Ryan CJ; Harzstark A; Derleth C; Kim W; Friedlander T; Lin AM; Rodvelt-Bagchi T; Dhawan M; Zhang L; Lee M; Siebeneck E; Hough J; Small EJ
Urol Oncol; 2017 Apr; 35(4):149.e7-149.e13. PubMed ID: 28161323
[TBL] [Abstract][Full Text] [Related]
10. Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer.
Nozawa M; Mukai H; Takahashi S; Uemura H; Kosaka T; Onozawa Y; Miyazaki J; Suzuki K; Okihara K; Arai Y; Kamba T; Kato M; Nakai Y; Furuse H; Kume H; Ide H; Kitamura H; Yokomizo A; Kimura T; Tomita Y; Ohno K; Kakehi Y
Int J Clin Oncol; 2015 Oct; 20(5):1026-34. PubMed ID: 25809824
[TBL] [Abstract][Full Text] [Related]
11. Weekly cabazitaxel plus prednisone is effective and less toxic for 'unfit' metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial.
Climent MÁ; Pérez-Valderrama B; Mellado B; Fernández Parra EM; Fernández Calvo O; Ochoa de Olza M; Muinelo Romay L; Anido U; Domenech M; Hernando Polo S; Arranz Arija JÁ; Caballero C; Juan Fita MJ; Castellano D
Eur J Cancer; 2017 Dec; 87():30-37. PubMed ID: 29102858
[TBL] [Abstract][Full Text] [Related]
12. Peg-filgrastim and cabazitaxel in prostate cancer patients.
Di Lorenzo G; DʼAniello C; Buonerba C; Federico P; Rescigno P; Puglia L; Ferro M; Bosso D; Cavaliere C; Palmieri G; Sonpavde G; De Placido S
Anticancer Drugs; 2013 Jan; 24(1):84-9. PubMed ID: 23044721
[TBL] [Abstract][Full Text] [Related]
13. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.
Corn PG; Heath EI; Zurita A; Ramesh N; Xiao L; Sei E; Li-Ning-Tapia E; Tu SM; Subudhi SK; Wang J; Wang X; Efstathiou E; Thompson TC; Troncoso P; Navin N; Logothetis CJ; Aparicio AM
Lancet Oncol; 2019 Oct; 20(10):1432-1443. PubMed ID: 31515154
[TBL] [Abstract][Full Text] [Related]
14. Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme.
Heidenreich A; Scholz HJ; Rogenhofer S; Arsov C; Retz M; Müller SC; Albers P; Gschwend J; Wirth M; Steiner U; Miller K; Heinrich E; Trojan L; Volkmer B; Honecker F; Bokemeyer C; Keck B; Otremba B; Ecstein-Fraisse E; Pfister D
Eur Urol; 2013 Jun; 63(6):977-82. PubMed ID: 23116658
[TBL] [Abstract][Full Text] [Related]
15. Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.
Armstrong AJ; Humeniuk MS; Healy P; Szmulewitz R; Winters C; Kephart J; Harrison MR; Martinez E; Mundy K; Halabi S; George D
Prostate; 2017 Mar; 77(4):385-395. PubMed ID: 27862097
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer.
Clément-Zhao A; Auvray M; Aboudagga H; Blanc-Durand F; Angelergues A; Vano YA; Mercier F; El Awadly N; Verret B; Thibault C; Oudard S
BJU Int; 2018 Feb; 121(2):203-208. PubMed ID: 28370882
[TBL] [Abstract][Full Text] [Related]
17. Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial.
Baciarello G; Delva R; Gravis G; Tazi Y; Beuzeboc P; Gross-Goupil M; Bompas E; Joly F; Greilsamer C; Hon TNT; Barthelemy P; Culine S; Berdah JF; Deblock M; Ratta R; Flechon A; Cheneau C; Maillard A; Martineau G; Borget I; Fizazi K;
Eur Urol; 2022 Mar; 81(3):234-240. PubMed ID: 34789394
[TBL] [Abstract][Full Text] [Related]
18. An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA).
Carles J; Pichler A; Korunkova H; Tomova A; Ghosn M; El Karak F; Makdessi J; Koroleva I; Barnes G; Bury D; Özatilgan A; Hitier S; Katolicka J
BJU Int; 2019 Mar; 123(3):456-464. PubMed ID: 30098093
[TBL] [Abstract][Full Text] [Related]
19. Cabazitaxel multiple rechallenges in metastatic castration-resistant prostate cancer.
Pobel C; Auclin E; Teyssonneau D; Laguerre B; Cancel M; Boughalem E; Noel J; Brachet PE; Maillet D; Barthelemy P; Helissey C; Thibault C; Oudard S
Cancer Med; 2021 Sep; 10(18):6304-6309. PubMed ID: 34382352
[TBL] [Abstract][Full Text] [Related]
20. Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.
Oudard S; Fizazi K; Sengeløv L; Daugaard G; Saad F; Hansen S; Hjälm-Eriksson M; Jassem J; Thiery-Vuillemin A; Caffo O; Castellano D; Mainwaring PN; Bernard J; Shen L; Chadjaa M; Sartor O
J Clin Oncol; 2017 Oct; 35(28):3189-3197. PubMed ID: 28753384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
